Solid lipid nanoparticle-based vectors intended for the treatment of X-linked juvenile retinoschisis by gene therapy: In vivo approaches in Rs1h-deficient mouse model

Journal of Controlled Release

Volumn 217, Issue , 2015, Pages 273-283

  Apaolaza, P S ^a   Del Pozo Rodriguez A ^a   Torrecilla, J ^a   Rodriguez Gascon A ^a   Rodriguez J M ^a   Friedrich, U ^b   Weber, B H F ^b   Solinis M A ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Dextran; Gene therapy; Hyaluronic acid; Non viral vector; Solid lipid nanoparticles; X linked juvenile retinoschisis

Indexed keywords

DEXTRAN; DISEASES; DRUG THERAPY; ENCODING (SYMBOLS); GENE TRANSFER; GENES; HYALURONIC ACID; IMAGE CODING; MAMMALS; NANOPARTICLES; OPHTHALMOLOGY; ORGANIC ACIDS; PROTEINS; VECTORS; VISION AIDS;

ANIONIC POLYSACCHARIDES; GREEN FLUORESCENT PROTEIN; INTRAVITREAL INJECTION; NONVIRAL VECTORS; RETINAL DEGENERATIVE DISEASE; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES; X-LINKED JUVENILE RETINOSCHISIS;

GENE THERAPY;

DEXTRAN; GREEN FLUORESCENT PROTEIN; HYALURONIC ACID; POLYSACCHARIDE; PROTAMINE; RETINOSCHISIN; SOLID LIPID NANOPARTICLE; CELL ADHESION MOLECULE; DNA; EYE PROTEIN; LIPID; NANOPARTICLE; RS1H PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; RETINAL THICKNESS; RETINOSCHISIS; SUBRETINAL DRUG ADMINISTRATION; X LINKED JUVENILE RETINOSCHISIS; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; DEFICIENCY; GENE THERAPY; GENETICS; METABOLISM; PROCEDURES; RETINA; TRANSGENIC MOUSE;

ANIMALS; CELL ADHESION MOLECULES; CELL LINE; DNA; EYE PROTEINS; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; LIPIDS; MICE, INBRED C57BL; MICE, TRANSGENIC; NANOPARTICLES; RETINA; RETINOSCHISIS;

EID: 84942891094     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.033     Document Type: Article

References (40)

1. S.K. Sikkink, S. Biswas, N.R. Parry, P.E. Stanga, and D. Trump X-linked retinoschisis: an update J. Med. Genet. 44 2007 225 232
2. L.C. Byrne, B.E. Oztürk, T. Lee, C. Fortuny, M. Visel, D. Dalkara, and et al. Retinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h -/- mouse Gene Ther. 6 2014 585 592
3. A. Tantri, T.R. Vrabec, A. Cu-Unjieng, A. Frost Jr., W.H. Annesley, and L.A. Donoso X-linked retinoschisis: a clinical and molecular genetic review Surv. Ophthalmol. 49 2004 214 230
4. B.H. Weber, H. Schrewe, L.L. Molday, A. Gehrig, K.L. White, M.W. Seeliger, and et al. Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure Proc. Natl. Acad. Sci. U. S. A. 99 2002 6222 6227
5. Y. Zeng, Y. Takada, S. Kjellstrom, K. Hiriyanna, A. Tanikawa, E. Wawrousek, and et al. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis Invest. Ophthalmol. Vis. Sci. 45 2004 3279 3285
6. S.H. Min, L.L. Molday, M.W. Seeliger, A. Dinculescu, A.M. Timmers, A. Janssen, and et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis Mol. Ther. 12 2005 644 651
7. S. Kjellstrom, R.A. Bush, Y. Zeng, Y. Takada, and P.A. Sieving Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration Invest. Ophthalmol. Vis. Sci. 48 2007 3837 3845
8. A. Janssen, S.H. Min, L.L. Molday, N. Tanimoto, M.W. Seeliger, W.W. Hauswirth, and et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse Mol. Ther. 16 2008 1010 1017
9. Y. Takada, C. Vijayasarathy, Y. Zeng, S. Kjellstrom, R.A. Bush, and P.A. Sieving Synaptic pathology in retinoschisis knockout (Rs1 -/y) mouse retina and modification by rAAV-Rs1 gene delivery Invest. Ophthalmol. Vis. Sci. 49 2008 3677 3686
10. T.K. Park, Z. Wu, S. Kjellstrom, Y. Zeng, R.A. Bush, P.A. Sieving, and et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse Gene Ther. 16 2009 916 926
11. D. Dalkara, L.C. Byrne, R.R. Klimczak, M. Visel, L. Yin, W.H. Merigan, and et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous Sci. Transl. Med. 5 2013 189ra76
12. C.E. Thomas, A. Ehrhardt, and M.A. Kay Progress and problems with the use of viral vectors for gene therapy Nat. Rev. Genet. 4 2003 346 358
13. T.B. Lentz, S.J. Gray, and R.J. Samulski Viral vectors for gene delivery to the central nervous system Neurobiol. Dis. 48 2012 179 188
14. A. Pensado, B. Seijo, and A. Sanchez Current strategies for DNA therapy based on lipid nanocarriers Expert Opin. Drug Deliv. 11 2014 1721 1731
15. A. Rodríguez-Gascón, A. del Pozo-Rodríguez, and M.A. Solinís Non-viral systems in gene therapy F. Martin, Gene Therapy - Tools and Potential Applications 2013 InTech Rijeka 3 33
16. A. Rodríguez-Gascón, M.A. Solinís, A. del Pozo-Rodríguez, D. Delgado, J.L. Pedraz, Lipid nanoparticles for gene therapy. US 20120183589 A1, 2012.
17. A. del Pozo-Rodríguez, D. Delgado, A. Rodríguez-Gascón, and M.A. Solinís Lipid nanoparticles as drug/gene delivery systems to the retina J. Ocul. Pharmacol. Ther. 29 2013 173 188
18. A. del Pozo-Rodríguez, M.A. Solinís, A.R. Gascón, and J.L. Pedraz Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy Eur. J. Pharm. Biopharm. 71 2009 181 189
19. D. Delgado, A. del Pozo-Rodríguez, M.A. Solinís, and A. Rodríguez-Gascón Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway Eur. J. Pharm. Biopharm. 79 2011 495 502
20. A. del Pozo-Rodríguez, S. Pujals, D. Delgado, M.A. Solinís, A. Rodríguez-Gascón, E. Giralt, and et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors J. Control. Release 133 2009 52 59
21. D. Delgado, A. del Pozo-Rodríguez, M.A. Solinís, M. Avilés-Triqueros, B.H. Weber, E. Fernández, and et al. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis Hum. Gene Ther. 4 2012 345 355
22. D. Delgado, A. del Pozo-Rodríguez, M.A. Solinís, A. Bartkowiak, and A. Rodríguez-Gascón New gene delivery system based on oligochitosan and solid lipid nanoparticles: 'in vitro' and 'in vivo' evaluation Eur. J. Pharm. Sci. 50 2013 484 491
23. P.S. Apaolaza, D. Delgado, A. del Pozo-Rodríguez, A. Rodríguez-Gascón, and M.A. Solinís A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases Int. J. Pharm. 465 2014 413 426
24. U. Friedrich, H. Stöhr, D. Hilfinger, T. Loenhardt, M. Schachner, T. Langmann, and et al. The Na/K-ATPase is obligatory for membrane anchorage of retinoschisin, the protein involved in the pathogenesis of X-linked juvenile retinoschisis Hum. Mol. Genet. 20 2011 1132 1142
25. T. Matsuda, and C.L. Cepko Electroporation and RNA interference in the rodent retina in vivo and in vitro Proc. Natl. Acad. Sci. USA 101 2004 16 22
26. A. del Pozo-Rodríguez, D. Delgado, M.A. Solinís, A. Rodríguez-Gascón, and J.L. Pedraz Solid lipid nanoparticles: formulation factors affecting cell transfection capacity Int. J. Pharm. 339 2007 261 268
27. D. Delgado, A. Rodríguez-Gascón, A. del Pozo-Rodríguez, E. Echevarría, A. Pérez Ruiz de garibay, J.M. Rodríguez, and et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice Int. J. Pharm. 425 2012 35 43
28. J. Torrecilla, A. del Pozo-Rodríguez, P.S. Apaolaza, M.A. Solinís, and A. Rodríguez-Gascón Solid lipid nanoparticles as on-viral vector for the treatment of chronic hepatitis C by RNA interference Int. J. Pharm. 479 2015 181 188
29. A. Rodríguez-Gascón, M.A. Solinís, A. del Pozo-Rodríguez, D. Delgado, E. Fernández, Lipid nanoparticles for treating ocular diseases. WO 2012085318 A1, 2012.
30. K. Raemdonck, T.F. Martens, K. Braeckmans, J. Demeester, and S.C. De Smedt Polysaccharide-based nucleic acid nanoformulations Adv. Drug Deliv. Rev. 65 2013 1123 1147
31. M. de la Fuente, B. Seijo, and M.J. Alonso Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy Invest. Ophthalmol. Vis. Sci. 49 2008 2016 2024
32. T. Ito, Y. Koyama, and M. Otsuka Analysis of the surface structure of DNA/polycation/hyaluronic acid ternary complex by Raman microscopy J. Pharmaceut. Biomed. 51 2010 268 272
33. S.K. Powell, R. Rivera-Soto, and S.J. Gray Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy Discov. Med. 19 2015 49 57
34. J. Mains, and C.G. Wilson The vitreous humor as a barrier to nanoparticle distribution J. Ocul. Pharmacol. Ther. 29 2013 143 150
35. T.F. Martens, K. Remaut, H. Deschout, J.F.J. Engbersen, W.E. Hennink, M.J. van Steenbergen, and et al. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy J. Control. Release 202 2015 83 92
36. R.S. Molday, U. Kellner, and B.H. Weber X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms Prog. Retin. Eye Res. 31 2012 195 212
37. S. Veleri, C.H. Lazar, B. Chang, P.A. Sieving, E. Banin, and A. Swaroop Biology and therapy of inherited retinal degenerative disease: insights from mouse models Dis. Model. Mech. 8 2015 109 129
38. A. Gehrig, A. Janssen, F. Horling, C. Grimm, and B.H.F. Weber The role of caspases in photoreceptor cell death of the retinoschisin-deficient mouse Cytogenet. Genome Res. 115 2006 35 44
39. A. Gehrig, T. Langmann, F. Horling, A. Janssen, M. Bonin, M. Walter, and et al. Genome-wide expression profiling of the retinoschisin-deficient retina in early postnatal mouse development Invest. Ophthalmol. Vis. Sci. 48 2007 891 900
40. M.A. Solinís, A. del Pozo-Rodríguez, P.S. Apaolaza, A. Rodríguez-Gascón, Treatment of ocular disorders by gene therapy, Eur. J. Pharm. Biopharm. http://dx.doi.org/10.1016/j.ejpb.2014.12.022.